Immune therapy for prostate cancer Journal Article

Authors: Yeku, O.; Slovin, S. F.
Article Title: Immune therapy for prostate cancer
Abstract: Immunotherapy for castration-resistant prostate cancer has continued to be an area of active research over the last several years. The enthusiasm of this approach has been based on the assumption of better tolerability and that using the body's own immune system may be more effective than either hormonal or chemotherapy. Sipuleucel-T, a dendritic cell-based vaccine, is the only approved agent in this class for the management of castrate-resistant prostate cancer. Although sipuleucel-T increases overall survival without any significant changes in progression-free survival, other forms of immunotherapy such as PSA-TRICOM, ipilimumab, and chimeric antigen receptor T cell therapy are in advanced stages of clinical development. Immune biomarkers are being developed to assess response to these treatments and also to understand how the immune system responds to these respective therapies. Combinations of immunotherapy with androgen deprivation, radiation therapy, and chemotherapy have also been explored with varying results. This review discusses the mechanisms, key preclinical and clinical data, and perspectives for immunotherapeutic agents in the treatment scheme for castrate-resistant prostate cancer. © 2016 Wolters Kluwer Health, Inc.
Keywords: immunotherapy; sipuleucel-t; management of castration-resistant prostate cancer
Journal Title: The Cancer Journal
Volume: 22
Issue: 5
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2016-09-01
Start Page: 334
End Page: 341
Language: English
DOI: 10.1097/ppo.0000000000000223
PROVIDER: scopus
PUBMED: 27749327
PMCID: PMC5117426
Notes: Review -- Export Date: 2 November 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Susan Slovin
    184 Slovin
  2. Oladapo Olumoroti Yeku
    11 Yeku
Related MSK Work